Lakefront Biotherapeutics American Depositary Shares (LKFT) Expected to Release Earnings on Monday

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) will likely be releasing its Q2 2026 results after the market closes on Monday, August 10th. Analysts expect the company to announce earnings of ($0.9672) per share and revenue of $7.29 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 11, 2026 at 8:00 AM ET.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.25 earnings per share for the quarter, beating the consensus estimate of ($1.27) by $1.52. The firm had revenue of $8.75 million during the quarter, compared to analysts’ expectations of $11.26 million. On average, analysts expect Lakefront Biotherapeutics American Depositary Shares to post $-11 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Lakefront Biotherapeutics American Depositary Shares Trading Down 1.7%

Lakefront Biotherapeutics American Depositary Shares stock opened at $26.76 on Monday. Lakefront Biotherapeutics American Depositary Shares has a 52 week low of $26.42 and a 52 week high of $37.78. The stock has a 50-day moving average price of $28.81 and a 200 day moving average price of $30.41. The stock has a market cap of $1.76 billion, a PE ratio of -18.98 and a beta of 0.25.

Analysts Set New Price Targets

LKFT has been the topic of several recent analyst reports. Morgan Stanley initiated coverage on Lakefront Biotherapeutics American Depositary Shares in a research note on Friday, July 10th. They issued an “equal weight” rating and a $30.00 price target on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, May 26th. Zacks Research upgraded Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a research report on Monday, June 8th. Finally, Wall Street Zen cut shares of Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $34.33.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Jane Street Group LLC raised its holdings in Lakefront Biotherapeutics American Depositary Shares by 2,245.7% during the 1st quarter. Jane Street Group LLC now owns 110,783 shares of the biotechnology company’s stock valued at $2,783,000 after buying an additional 115,946 shares during the period. Geode Capital Management LLC bought a new stake in shares of Lakefront Biotherapeutics American Depositary Shares in the 2nd quarter worth about $220,000. Jump Financial LLC purchased a new position in shares of Lakefront Biotherapeutics American Depositary Shares during the 2nd quarter worth about $692,000. Boothbay Fund Management LLC bought a new position in Lakefront Biotherapeutics American Depositary Shares during the 2nd quarter valued at about $612,000. Finally, Engineers Gate Manager LP purchased a new stake in Lakefront Biotherapeutics American Depositary Shares in the 2nd quarter worth about $560,000. 32.46% of the stock is owned by hedge funds and other institutional investors.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.